MSTP Student
Graduate Student
This study was led by former graduate student Vaciry Li with great efforts from many intra- and inter-group collaborations. Congratulations to all!
In this study, we showed that context and allele-dependent transcriptome and cistrome reprogramming in ESR1 mutation cell models, which elicit diverse metastatic phenotypes related to cell-cell adhesion, cell-ECM adhesion and migration driven by increased desmosome/gap junctions, dampened TIMP3-MMP axis and Wnt pathway. Importantly, some of these pathways can pharmacologically targeted and reveals novel therapeutic strategies.
Our paper is out on ESTROGEN RECEPTOR MUTATIONS – so much more than endocrine resistance. Multiple roles in #metastaticbreastcancer Great work by @ZheqiL @UPMCHillmanCC @MageeWomens now postdoc @DanaFarber @Adrianvlee https://t.co/X1baEXelai pic.twitter.com/nI7VNbrzau
— Dr. Steffi Oesterreich (@oesterreichs) January 27, 2022
Led by PhD student Neil Carleton and senior authors Adrian Lee, Priscilla McAuliffe, and Steffi Oesterreich, we review key considerations for “right-sizing” therapy options for older women with ER+ breast cancer. With contributions from radiation, pathology, surgical oncology, radiation oncology, and medical oncology from the UPMC / Magee Women’s Hospital breast cancer group, this collaborative effort touches on optimizing quality of life along with new translational studies that may impact future treatment of these patients.
Check it out at: https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00280-4/fulltext.
The Lee/Oesterreich lab is delighted to receive two grant awards from the Breast Cancer Alliance (http://breastcanceralliance.org/).
The BCA selected to fund our projects entitled ‘Therapeutic targeting of novel pathways in breast cancer brain metastases’ and ‘Understanding the importance of ESR1 fusion genes in metastatic breast cancer”. The grants provide one year of funding support for these exciting projects.
We are very grateful for the funding to continue our quest to better understand and target endocrine resistant breast cancer.
Steffi meets with members of LBCA advocacy group (https://lobularbreastcancer.org/), and discusses progress and challenges for ILC research at the Northwest Metastatic Breast Cancer Conference (NWMBCC).
The presentation was live streamed, and can be seen here: https://www.facebook.com/lobularbreastcanceralliance/videos/553742191751845/.
Of note, Leigh Pate, founder of LBCA, receives the Beth Caldwell Breakthrough Leadership award.
